Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Emerging Concepts in Multiple Myeloma

June 29th 2015

Diagnostic and Response Criteria in Multiple Myeloma

June 29th 2015

ENDEAVOR and CHAMPION Trials in Multiple Myeloma

June 29th 2015

Second-Generation Agents in Relapsed Multiple Myeloma

June 29th 2015

Triplet Therapy in Multiple Myeloma

June 29th 2015

HDAC Inhibitors in Multiple Myeloma

June 29th 2015

Treating Relapsed and Refractory Multiple Myeloma

June 29th 2015

Continuous Therapy in Multiple Myeloma

June 29th 2015

Maintenance Therapy in Multiple Myeloma

June 29th 2015

Defining High-Risk Multiple Myeloma

June 29th 2015

Evolving Role of Stem Cell Transplant in Multiple Myeloma

June 29th 2015

Frontline Treatments for Multiple Myeloma

June 29th 2015

Treatment Goals in Newly Diagnosed Multiple Myeloma

June 29th 2015

Elotuzumab and Daratumumab in Multiple Myeloma

June 29th 2015

Introduction: Monoclonal Antibodies in Multiple Myeloma

June 29th 2015

Venetoclax Combination Shows Antitumor Activity in Advanced Myeloma

June 20th 2015

A three-drug combination comprising the novel Bcl-2 inhibitor venetoclax, bortezomib, and dexamethasone demonstrated a clinical benefit in heavily pretreated patients with relapsed/refractory multiple myeloma.

Panobinostat PFS Benefit Extended in PANORAMA-1 Subgroup Analysis

June 13th 2015

The addition of panobinostat to bortezomib and dexamethasone improved progression-free survival by 7.8 months in a subgroup of 147 patients with multiple myeloma who had received at least 2 prior treatments, including bortezomib and an immunomodulatory agent.

Treating Newly Diagnosed Multiple Myeloma

June 13th 2015

Maintenance Therapy Improves Outcomes in Multiple Myeloma

June 13th 2015

Maximizing Stem Cell Transplantation in Multiple Myeloma

June 13th 2015